3billion Presents the Family Insight Test at Prenatal Genetic Counseling Symposium

“Finding Genetic Causes Without a Child’s Sample”

■ 3billion presents the Family Insight Test at the 2026 Prenatal Genetic Counseling and Genomic Precision Medicine Symposium

■ Family-based genomic analysis can help identify potential genetic causes and assess recurrence risk even when a child’s sample is unavailable

SEOUL, South Korea, September 7, 2026 — 3billion, an AI-powered rare disease diagnostics company, announced that it presented the Family Insight Test, its family-based precision genomic testing service, at the 2026 Symposium on Prenatal Genetic Counseling and Genomic Precision Medicine hosted by CHA Bundang Medical Center on September 6. The company also discussed opportunities to expand clinical adoption and collaboration in Korea.

Held at the CHA Bio Complex in Pangyo, the symposium focused on the theme “From Preconception to Embryos, Fetuses, and Newborns—Connecting Screening, Diagnosis, Treatment, and Counseling.” More than 160 clinicians and experts, including obstetricians, attended to discuss discuss the latest research and clinical developments in noninvasive prenatal testing (NIPT), prenatal genetic testing, and precision diagnostics for rare genetic diseases.

Dr. Gohun Seo, Chief Medical Officer of 3billion, introduced the Family Insight Test and presented real-world applications in a session titled “Finding Answers Without a Child’s Sample: Recurrence Risk and the Family Insight Test.” Dr. Seo explained that when a sample from a child suspected of having a genetic disorder is unavailable, phenotypic information from the child or other family members can guide genomic analysis of available relatives, helping identify potential genetic causes and estimate recurrence risk.

Since its launch in March, the Family Insight Test has seen rapid growth in orders in Korea and overseas. Unlike expanded carrier screening (ECS), which assesses carrier status using a predefined gene list, the Family Insight Test integrates clinical history, family history, and information from the reproductive partner. It reports not only pathogenic (P) and likely pathogenic (LP) variants but also selected variants of uncertain significance (VUS). The test can also be performed using a single individual’s sample when samples from other family members are unavailable.

3billion also operated an exhibition booth, where its team consulted clinicians on incorporating the Family Insight Test into clinical practice. Discussions focused on cases involving recurrent pregnancy loss, infertility, and fetal or neonatal death, covering patient eligibility, testing scope and criteria, result interpretation, and report delivery. These conversations also helped the company assess clinical needs and explore collaboration opportunities to expand adoption in Korea.

“The Family Insight Test is a precision genetic testing service that helps families who have experienced reproductive challenges or have a family history of genetic disease better understand potential genetic causes and recurrence risk,” said Changwon Keum, CEO of 3billion. “We will expand our collaboration with clinicians in Korea to help more families plan for pregnancy based on accurate genetic information.”

The symposium also highlighted two genomic newborn screening and diagnostic projects involving 3billion: KNeoRapidWGS, which uses rapid whole-genome sequencing to identify genetic causes in critically ill infants in neonatal intensive care units; and K-gNBS, which uses whole-genome sequencing to assess rare disease risks in healthy newborns. Updates and results from both projects were presented.